Dose optimization of somatostatin analogues for acromegaly patients.

Item

http://www.wikidata.org/entity/Q43116265

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Dose optimization of somatostatin analogues for acromegaly patients.

@en

Dose optimization of somatostatin analogues for acromegaly patients.

@nl

type

Item

label

Dose optimization of somatostatin analogues for acromegaly patients.

@en

Dose optimization of somatostatin analogues for acromegaly patients.

@nl

prefLabel

Dose optimization of somatostatin analogues for acromegaly patients.

@en

Dose optimization of somatostatin analogues for acromegaly patients.

@nl

P1476

Dose optimization of somatostatin analogues for acromegaly patients.

@en

P2093

Lombardi G

http://www.w3.org/2001/XMLSchema#string

P2860

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.

Guidelines for acromegaly management.

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

Consensus statement: medical management of acromegaly.

Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.

Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.

Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.

P2888

bf03346566

P304

125-127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF03346566

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Annamaria Colao

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1045271167

http://www.w3.org/2001/XMLSchema#string

P698

20348838

http://www.w3.org/2001/XMLSchema#string